TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Dec 16, 2022 2:31pm
83 Views
Post# 35176446
RE:RE:RE:RE:panobinostat, lomustine, xB3-bevacizumab
RE:RE:RE:RE:panobinostat, lomustine, xB3-bevacizumabJDavenport wrote: poofster says, "xB3 has never been in a stronger position."
That's true, I agree.
And Bioasis shareholders have never been in a weaker position.
jd
Given BTI's share price of C$.15 with virtually no volume, the debt, and the state of the markets with many biotech stocks trading below cash if BTI tried to raise US$10 million with warrants all on its own given its history how much dilution would it suffer? It could still be 2 years from a clinical trial meaning even more dilution. It wasn't a good situation.